Gotratix
Muscle / RecoveryAlso known as: Muscle peptide complex
Mechanism
An oral peptide complex derived from muscle tissue. It supports muscle fiber regeneration and helps reduce age-related muscle loss (sarcopenia). Used as an oral bioregulator for maintaining muscle mass and function in aging populations.
Technical detail
Peptide complex isolated from animal skeletal muscle tissue, containing short peptides targeting myocytes and satellite cells. Proposed mechanism: modulates expression of myogenic regulatory factors (MyoD, myogenin, MRF4), structural proteins (myosin heavy chain isoforms, desmin), and anti-atrophy genes (inhibiting MAFbx/atrogin-1 and MuRF1 expression). In aged animal models, improved muscle fiber cross-sectional area, reduced fibrosis, and increased satellite cell activation markers. Russian gerontological studies report improved grip strength and muscle mass indices in elderly subjects. Part of Cytomax oral bioregulator series.
Effects
## Gotratix — System-by-System Effects ### Musculoskeletal System (Primary Target) - **Muscle tissue bioregulation**: Gotratix is a peptide bioregulator targeting skeletal muscle tissue. It is designed to restore optimal gene expression in aging muscle cells, supporting muscle protein synthesis, fiber integrity, and regenerative capacity. [Tier 2 — Khavinson bioregulator research] - **Sarcopenia prevention**: Primary intended use is combating age-related muscle loss (sarcopenia). By restoring youthful gene expression patterns in myocytes, gotratix may slow the decline in muscle mass and function that accelerates after age 50. [Tier 2-3] - **Muscle recovery**: May support post-exercise muscle repair and adaptation by optimizing the transcriptional response to mechanical stress. [Tier 3] - **Muscle fiber quality**: Supports maintenance of type II (fast-twitch) muscle fibers, which are preferentially lost during aging. [Tier 3] ### Metabolic System - **Metabolic rate support**: Maintaining muscle mass supports resting metabolic rate. By preserving muscle, gotratix indirectly supports metabolic health. [Tier 3 — indirect effect] - **Glucose disposal**: Skeletal muscle is the largest glucose disposal organ. Maintaining muscle mass and quality supports insulin sensitivity. [Tier 1 for muscle-glucose biology, Tier 3 for gotratix-specific effect] ### Functional Capacity - **Physical performance**: Supporting muscle integrity translates to maintained physical function, balance, and independence in aging populations. [Tier 3] - **Fall prevention**: Indirectly, by preserving muscle mass and strength, gotratix may contribute to fall prevention in the elderly — a critical health outcome. [Tier 3]
Practitioner Guide
## Gotratix — Practitioner Guide ### Clinical Profile Gotratix is a short peptide bioregulator targeting skeletal muscle tissue. Part of the Khavinson cytogens class. Used for sarcopenia prevention and muscle maintenance in aging. ### Typical Protocols - **Standard course**: 1-2 capsules daily for 30 days, repeat 2-3 times per year - **Anti-sarcopenia**: 2 capsules daily for 30 days alongside resistance training program - **Combined with exercise**: Timed to coincide with initiation of a new exercise program to optimize the adaptive response ### Best Candidates - Aging patients (50+) with declining muscle mass or strength - Patients with early sarcopenia detected on DEXA or grip strength testing - Post-illness patients recovering muscle mass after prolonged bed rest - Elderly patients starting exercise programs (support the adaptive response) - Patients who want to maintain muscle but cannot use hormonal therapies ### Combination Strategies - **Anti-sarcopenia comprehensive**: Gotratix + protein optimization (1.2-1.6g/kg/day) + resistance training + creatine (5g/day) - **Bioregulator muscle stack**: Gotratix (muscle) + Sigumir (joints) + Ventfort (vessels) — comprehensive musculoskeletal support - **Growth support**: Gotratix + MK-677 or GH peptides — bioregulation plus GH axis support - **Recovery optimization**: Gotratix + BPC-157 + TB-500 — tissue repair and muscle support ### Clinical Observations - Best results when combined with resistance training — gotratix appears to enhance the adaptive response to exercise - Elderly patients report improved recovery from exercise sessions - Modest but clinically meaningful improvements in grip strength and functional measures over 2-3 courses - Very well tolerated with no reported adverse effects - Effects are subtle and cumulative — patients should not expect dramatic muscle growth ### Limitations - Not a replacement for exercise, protein, or hormonal therapy in severe sarcopenia - Evidence base is limited to bioregulator research program - Cannot replace testosterone or other anabolic agents for significant muscle building - Oral bioavailability of short peptides remains a general concern for the bioregulator class
Research Summary
## Gotratix — Research Summary ### Tier 1 - No Western RCTs available. ### Tier 2 - Khavinson bioregulator research program publications on muscle-targeting peptide bioregulators. - In vitro studies showing modulation of gene expression in cultured myocytes. - Animal studies demonstrating improved muscle function markers in aged rodents. ### Tier 3 - Clinical observations from European practitioners report improved muscle function and reduced sarcopenia progression. - Practitioner consensus supports use as adjunct to exercise in aging populations. - Best results reported when combined with resistance training and protein optimization. ### Key Research Gaps - No RCTs or placebo-controlled studies - No pharmacokinetic validation of oral peptide absorption - No head-to-head comparison with established sarcopenia interventions (exercise, protein, creatine, testosterone) - Long-term outcomes data limited to clinical observation